CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 194 enrolled
Drug / intervention
Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00974090
NCT00974090Phase 3Completed
CompareCT.gov

A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus

Tanabe Pharma Corporation·interventional·Posted Sep 10, 2009·Updated Jan 5, 2026

In Brief

A Phase 3 clinical trial evaluating Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea) and Teneli / Teneli + SU for Type 2 Diabetes Mellitus. Completed, enrolled 194 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2009
Enrollment StartSep 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.8 years ago

Interventions

Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)drug

Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea

Teneli / Teneli + SUdrug

Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea